Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$8.94 USD
+0.70 (8.50%)
Updated Nov 21, 2024 03:59 PM ET
After-Market: $8.94 0.00 (0.00%) 5:16 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Price, Consensus and EPS Surprise
CRVS 8.94 +0.70(8.50%)
Will CRVS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for CRVS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRVS
Corvus (CRVS) is on the Move, Here's Why the Trend Could be Sustainable
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
CRVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 Weeks
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround
Corvus (CRVS) Upgraded to Buy: What Does It Mean for the Stock?
Other News for CRVS
Corvus Pharmaceuticals announces preclinical dataon soquelitinib
Corvus Pharmaceuticals announces preclinical dataon soquelitinib
Corvus Pharmaceuticals’ Soquelitinib: Optimism and Market Potential Drive Buy Rating
Corvus Pharmaceuticals price target raised to $13 from $8 at Jefferies
Corvus Pharmaceuticals price target raised by $5 at Jefferies, here's why